Boehringer Ingelheim Corporation and Eli Lilly and Company Release: Trajenta® (linagliptin) Receives Approval for the Treatment of Type 2 Diabetes in Europe

Published: Aug 25, 2011

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received Marketing Authorisation from the European Commission for Trajenta® (linagliptin) 5 mg film-coated tablets for the treatment of adults with type 2 diabetes. The European Commission has approved linagliptin in combination with metformin and metformin plus sulphonylurea.1 Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.1

Back to news